Wu Yifang
Senior vice president and Chief operating officer @ Fosun Pharma
Shanghai, China
Wu Yifang is a corporate round investor at Fosun Pharma in Shanghai focused on Artificial Intelligence and Health Care. Wu Yifang is based out of Shanghai, Shanghai and is the senior vice president and chief operating officer of Fosun Pharma. Wu previously worked at Wanbang Pharma as a director. Wu Yifang attended Saint Joseph’s University.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Wu Yifang invests in
Stages Wu Yifang invests in
Countries Wu Yifang invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Artificial Intelligence 2 (100%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Medical Device 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Corporate Round 1 (50%)
- Venture - Series Unknown 1 (50%)
Country
- China 1 (50%)
- Hong Kong 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Xingmai Technology is a scientific and technological innovation-oriented enterprise. | $14.8M / Venture - Series Unknown / Aug 02, 2022 | ||
| Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | Corporate Round / Jan 11, 2022 |
Co-Investors
About Fosun Pharma
Fosun Pharma is a biopharmaceutical and healthcare industry. Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. Fosun Pharma's operations strategically cover several important segments of the healthcare industryvalue-chain, including: pharmaceutical manufacturing, distribution and retail.
Fosun Pharma Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cui Zhiping
Vice President and General Manager of VC Investment Department
|
|||
Hongfei Jia
SVP, Joint Chief Investment Officer and General Manager of International Operations Department
|
|||
Wai Danny
Independent Non-Executive Director
|
|||
|
Wu Yifang
Senior vice president and Chief operating officer
|
|||
Zhou Biao
SVP, General Manager of Legal Department and General Manager of Independent Inspectors Department
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Wu Yifang invest in?
Wu Yifang invests primarily in Artificial Intelligence, Health Care and Biotechnology startups, most often at Corporate Round and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wu Yifang?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Wu Yifang last invest?
The most recent investment recorded for Wu Yifang closed in Aug 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
